Khalid et al. 2023. ROLE OF SGLT-2 INHIBITORS (GLIFLOZINS) AND CARDIORENAL OUTCOME IN PATIENTS WITH OR WITHOUT DIABETES. Journal of Population Therapeutics and Clinical Pharmacology. 30, 18 (Oct. 2023), 1001–1009. DOI:https://doi.org/10.53555/jptcp.v30i18.3220.